COMPANY PROFILE // THE 014 REPORT
Q32 Bio Inc.
QTTB (Nasdaq) · Formerly: Homology Medicines, Inc.
Assembled from 2 government sources in 0.1 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 3.01 filed: notice of delisting, of a failed continued-listing rule, or of a transfer of listing on 2025-05-23 (last 24 months).
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Q32 Bio Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in Waltham, MA; listed as QTTB (Nasdaq).[source] It reported revenue of $53.7 million for the fiscal year ended 2025-12-31.[source] It has filed 102 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-16.[source] Its largest institutional holders on 13F filings are ORBIMED ADVISORS LLC, Boxer Capital Management, LLC, Atlas Venture Life Science Advisors, LLC (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 8-K Item 3.01 filed.[source]
- red0
- amber1
- info0
- ORBIMED ADVISORS LLC$52.6M
- Boxer Capital Management, LLC$40.1M
- Atlas Venture Life Science Advisors, LLC$34.6M
- BVF INC/IL$29.9M
- RA CAPITAL MANAGEMENT, L.P.$29.7M
- Point72 Asset Management, L.P.$14.9M
- Opaleye Management Inc.$11.9M
- Logos Global Management LP$10.2M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Kalowski Lee · CFO and President (Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- Morrison Jodie Pope · CEO (Director,Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- Violette Shelia M. · Chief Scientific Officer (Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- GRAYZEL DAVID S. · Director · latest Form 4 2026-01-30 · filing · LinkedIn search
- Iwicki Mark T · Director · latest Form 4 2025-10-27 · filing · LinkedIn search
- LAPORTE KATHLEEN · Director · latest Form 4 2026-01-30 · filing · LinkedIn search
- Lundberg Sven Ante · Director · latest Form 4 2026-01-30 · filing · LinkedIn search
- Manke Isaac · Director · latest Form 4 2025-10-27 · filing · LinkedIn search
- TZIANABOS ARTHUR · Director · latest Form 4 2025-10-27 · filing · LinkedIn search
- Thistle Mary · Director · latest Form 4 2025-10-27 · filing · LinkedIn search
- Xu Diyong · Director · latest Form 4 2025-10-27 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Goodwin Procter LLP · Exhibit 5.1 legal opinion, S-3 filed 2026-07-17
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 24 CLEAR, 2 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001661998 | source |
| EIN | 47-3468154 | source |
| Business address (SEC) | 830 WINTER STREET, WALTHAM, MA, 02451 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
ADDRESS · ZIP CODE
Location context
At the same address (2)
- TScan Therapeutics, Inc. · SEC registrant
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- KALA BIO, Inc. · Iwicki Mark T
- Inhibikase Therapeutics, Inc. · Iwicki Mark T
- Precipio, Inc. · LAPORTE KATHLEEN
- Bolt Biotherapeutics, Inc. · LAPORTE KATHLEEN
- CERO THERAPEUTICS HOLDINGS, INC. · LAPORTE KATHLEEN
- Vor Biopharma Inc. · Lundberg Sven Ante
- Addex Therapeutics Ltd. · Manke Isaac
- OnKure Therapeutics, Inc. · Manke Isaac
- Stoke Therapeutics, Inc. · TZIANABOS ARTHUR
- Entrada Therapeutics, Inc. · Thistle Mary
- Aktis Oncology, Inc. · Thistle Mary
SEC registrants at the same address
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-16 name change Name changed from Q32 Bio Inc. · SEC EDGAR
- 2026-11-04 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-04 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-09-30 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-09-14 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-08-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-28 filing EFFECT · SEC EDGAR
- 2026-07-28 filing 424B3 · SEC EDGAR
- 2026-07-20 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-07-17 filing S-3 · SEC EDGAR
- 2026-07-15 filing 8-K items 1.01,9.01 · SEC EDGAR
- 2026-07-15 filing 424B5 · SEC EDGAR
- 2026-07-13 filing EFFECT · SEC EDGAR
- 2026-07-13 filing 424B5 · SEC EDGAR
- 2026-07-13 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-07-13 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-06-25 filing S-3 · SEC EDGAR
- 2026-06-16 filing 8-K items 5.07 · SEC EDGAR
- 2026-06-01 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-05-28 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-05-27 filing 8-K items 1.01,3.02,8.01,9.01 · SEC EDGAR
- 2026-05-06 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-05-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-30 filing ARS · SEC EDGAR
- 2026-04-30 filing DEFA14A · SEC EDGAR
- 2026-04-30 filing Proxy statement · SEC EDGAR
- 2026-04-24 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-04-24 filing 424B5 · SEC EDGAR
167 earlier entries
- 2026-03-27 filing 8-K items 1.01,9.01
- 2026-03-27 filing 424B5
- 2026-03-12 filing SCHEDULE 13D/A
- 2026-03-10 filing S-8
- 2026-03-10 filing Annual report (10-K)
- 2026-03-10 filing 8-K items 2.02,9.01
- 2026-02-17 filing 8-K items 1.01,8.01,9.01
- 2026-02-17 filing 424B5
- 2025-12-19 officer change 8-K items 5.02
- 2025-12-02 filing 144
- 2025-12-02 filing 144
- 2025-12-01 filing 8-K items 1.01,1.02,2.01,7.01,8.01,9.01
- 2025-11-13 filing Quarterly report (10-Q)
- 2025-11-13 filing 8-K items 2.02,9.01
- 2025-10-27 insider First Form 3/4/5 on record for GRAYZEL DAVID S. (Director)
- 2025-10-27 insider First Form 3/4/5 on record for Iwicki Mark T (Director)
- 2025-10-27 insider First Form 3/4/5 on record for LAPORTE KATHLEEN (Director)
- 2025-10-27 insider First Form 3/4/5 on record for Lundberg Sven Ante (Director)
- 2025-10-27 insider First Form 3/4/5 on record for Manke Isaac (Director)
- 2025-10-27 insider First Form 3/4/5 on record for TZIANABOS ARTHUR (Director)
- 2025-10-27 insider First Form 3/4/5 on record for Thistle Mary (Director)
- 2025-10-27 insider First Form 3/4/5 on record for Xu Diyong (Director)
- 2025-10-21 filing 8-K items 8.01,9.01
- 2025-08-28 filing UPLOAD
- 2025-08-28 insider First Form 3/4/5 on record for Kalowski Lee (CFO and President)
- 2025-08-28 insider First Form 3/4/5 on record for Morrison Jodie Pope (CEO)
- 2025-08-28 insider First Form 3/4/5 on record for Violette Shelia M. (Chief Scientific Officer)
- 2025-08-26 filing CORRESP
- 2025-08-06 filing Quarterly report (10-Q)
- 2025-08-06 filing 8-K items 2.02,9.01
- 2025-07-31 filing CORRESP
- 2025-07-30 filing UPLOAD
- 2025-06-25 officer change 8-K items 5.02,7.01,9.01
- 2025-06-17 filing 8-K items 3.03,5.03,5.07,9.01
- 2025-05-23 filing 8-K items 3.01
- 2025-05-08 filing Quarterly report (10-Q)
- 2025-05-08 filing 8-K items 2.02,9.01
- 2025-04-29 filing ARS
- 2025-04-29 filing DEFA14A
- 2025-04-29 filing Proxy statement
- 2025-04-25 officer change 8-K items 5.02
- 2025-04-21 filing EFFECT
- 2025-04-17 filing CORRESP
- 2025-04-16 filing EFFECT
- 2025-04-16 filing UPLOAD
- 2025-04-11 filing POS AM
- 2025-04-11 filing S-3
- 2025-04-11 filing PRE 14A
- 2025-03-11 filing S-8
- 2025-03-11 filing 424B3
- 2025-03-11 filing Annual report (10-K)
- 2025-03-11 filing 8-K items 2.02,9.01
- 2025-03-10 filing 424B3
- 2025-03-10 filing 8-K items 8.01,9.01
- 2025-02-10 filing 424B3
- 2025-02-10 filing 8-K items 2.05,7.01,9.01
- 2025-01-13 filing 8-K items 7.01,9.01
- 2024-12-11 filing 424B3
- 2024-12-11 filing 8-K items 7.01,8.01,9.01
- 2024-11-07 filing 424B3
- 2024-11-07 filing Quarterly report (10-Q)
- 2024-11-07 filing 8-K items 2.02,9.01
- 2024-08-08 filing 424B3
- 2024-08-08 filing Quarterly report (10-Q)
- 2024-08-08 filing 8-K items 2.02,9.01
- 2024-07-09 filing 424B3
- 2024-07-09 filing 8-K items 7.01,8.01,9.01
- 2024-05-31 filing S-8
- 2024-05-09 filing 424B3
- 2024-05-09 filing Quarterly report (10-Q)
- 2024-05-09 filing 8-K items 2.02,9.01
- 2024-04-29 filing EFFECT
- 2024-04-29 filing 424B3
- 2024-04-25 filing CORRESP
- 2024-04-25 filing UPLOAD
- 2024-04-19 filing Registration (S-1)
- 2024-04-12 filing 10-K/A
- 2024-04-04 filing SC 13D
- 2024-04-01 filing SC 13D
- 2024-03-28 filing SC 13D
- 2024-03-27 officer change 8-K items 1.01,2.01,2.02,2.03,3.02,3.03,4.01,5.01,5.02,5.03,5.06,7.01,9.01
- 2024-03-22 filing 8-K/A items 8.01
- 2024-03-22 name change Name changed from Homology Medicines, Inc.
- 2024-03-20 filing 8-K items 8.01
- 2024-03-15 filing 8-K items 5.07
- 2024-03-13 filing POS EX
- 2024-03-13 filing 424B3
- 2024-03-13 filing Annual report (10-K)
- 2024-03-11 filing 425
- 2024-03-11 filing 8-K items 8.01
- 2024-02-21 filing 425
- 2024-02-14 filing SEC STAFF LETTER
- 2024-02-14 filing EFFECT
- 2024-02-14 filing 424B3
- 2024-02-13 filing CORRESP
- 2024-02-13 filing S-4/A
- 2024-02-12 filing CORRESP
- 2024-02-12 filing S-4/A
- 2024-02-09 filing UPLOAD
- 2024-01-29 filing S-4/A
- 2024-01-26 filing CORRESP
- 2024-01-26 filing 425
- 2024-01-26 filing 8-K items 7.01,9.01
- 2024-01-23 filing SEC STAFF LETTER
- 2024-01-22 filing UPLOAD
- 2024-01-03 filing 425
- 2024-01-03 filing 8-K items 3.01,7.01,9.01
- 2023-12-18 filing S-4
- 2023-12-11 filing 3/A
- 2023-11-16 filing 425
- 2023-11-16 filing 425
- 2023-11-16 filing 425
- 2023-11-16 filing 425
- 2023-11-16 officer change 8-K items 1.01,3.02,5.01,5.02,9.01
- 2023-11-16 filing 425
- 2023-11-16 filing 8-K items 7.01,9.01
- 2023-11-14 filing Quarterly report (10-Q)
- 2023-10-10 filing 8-K items 7.01,9.01
- 2023-08-14 filing Quarterly report (10-Q)
- 2023-07-27 filing 8-K items 2.05,8.01
- 2023-06-14 filing 8-K items 5.07
- 2023-05-11 filing Quarterly report (10-Q)
- 2023-04-28 filing ARS
- 2023-04-28 filing DEFA14A
- 2023-04-28 filing Proxy statement
- 2023-03-17 filing EFFECT
- 2023-03-16 filing CORRESP
- 2023-03-14 filing UPLOAD
- 2023-03-09 filing S-3
- 2023-03-09 filing S-8
- 2023-03-09 filing Annual report (10-K)
- 2023-01-20 filing 3/A
- 2023-01-04 filing 8-K items 7.01,9.01
- 2022-11-10 filing Quarterly report (10-Q)
- 2022-09-08 officer change 8-K items 5.02,9.01
- 2022-08-15 filing Quarterly report (10-Q)
- 2022-06-16 filing 8-K items 5.07
- 2022-06-13 filing 8-K items 8.01
- 2022-05-16 filing Quarterly report (10-Q)
- 2022-04-29 filing DEFA14A
- 2022-04-29 filing Proxy statement
- 2022-04-21 officer change 8-K items 5.02,9.01
- 2022-03-23 filing Annual report (10-K)
- 2022-03-16 filing 8-K items 1.01,2.01,9.01
- 2022-02-18 filing 8-K items 7.01,9.01
- 2022-02-03 officer change 8-K items 1.01,5.02,7.01,9.01
- 2021-11-15 filing Quarterly report (10-Q)
- 2021-08-12 filing Quarterly report (10-Q)
- 2021-06-21 filing 8-K items 5.07
- 2021-05-06 filing Quarterly report (10-Q)
- 2021-04-29 filing DEFA14A
- 2021-04-29 filing Proxy statement
- 2021-04-19 filing SEC STAFF LETTER
- 2021-04-12 officer change 8-K items 5.02
- 2021-04-09 filing 8-K items 8.01,9.01
- 2021-04-08 filing 424B5
- 2021-04-07 filing 424B5
- 2021-03-22 filing SEC STAFF LETTER
- 2021-03-12 filing EFFECT
- 2021-03-11 filing POS AM
- 2021-03-11 filing Annual report (10-K)
- 2021-03-11 filing POSASR
- 2021-03-01 filing 8-K items 1.02
- 2021-02-08 filing 8-K items 8.01,9.01
- 2021-02-03 filing CT ORDER
- 2021-01-06 filing 8-K items 7.01,9.01
- 2020-12-18 filing 8-K items 5.03,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-04 (within 30 days) 10-Q filed
- 2026-11-04 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-30 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-14 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-05 (older) 10-Q filed
- 2026-08-05 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-28 (older) EFFECT filed
- 2026-07-28 (older) 424B3 filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:QTTB The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
3 possible matches held apart, matched by name only, not counted above; 2 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1661998 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | QTTB / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 473468154 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001661998 | SEC EDGAR / IRS |
| CUSIP | 746964105 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001661998 | SEC EDGAR |
possible match: matched by name only, not merged (1)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110070596168 (Q32 BIO) | name-exact: exact name match to 'Q32 Bio Inc.' (no other entity shares the name) | EPA ECHO facilities |
former name (shown apart, not merged) (2)
- former nameHomology Medicines, Inc · ClinicalTrials.gov
- former nameHOMOLOGY MEDICINES INC · EPA ECHO facilities
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $53,737,000 | 2025-12-31 | 10-K, XBRL Revenues | as filed | 2026-11-20 09:09 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $29,821,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 09:09 UTC | Report an error |
| Total assets (at 2025-12-31) | $61,776,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 09:09 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $42,014,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 09:09 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $48,297,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 09:09 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 09:09 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 09:09 UTC | Report an error |
| State of incorporation | DE | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 09:09 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 09:09 UTC | Report an error |
| Business address | 830 WINTER STREET, WALTHAM, MA, 02451 | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 09:09 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-16 | SEC EDGAR company profile | as filed | 2026-11-20 09:09 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$33,543,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 09:09 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $0 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-20 09:09 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $5,636,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 09:09 UTC | Report an error |
| Form D total offering amount (D filed 2017-08-10) | $83,500,008 | 2017-08-10 | D | as filed | 2026-11-20 09:09 UTC | Report an error |
| Form D total amount sold (D filed 2017-08-10) | $83,500,008 | 2017-08-10 | D | as filed | 2026-11-20 09:09 UTC | Report an error |
| Form D industry group | Pharmaceuticals | 2017-08-10 | D | as filed | 2026-11-20 09:09 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2017-08-10 | D | as filed | 2026-11-20 09:09 UTC | Report an error |
| Form D date of first sale | 2017-07-28 | 2017-08-10 | D | as filed | 2026-11-20 09:09 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001193125-26-446206
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$8,922,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-04 | 0001193125-26-446206 | 2026-11-20 09:09 UTC | Report an error |
| Cash and cash equivalents | $289,587,000 | at 2026-09-30 | 10-Q | 2026-11-04 | 0001193125-26-446206 | 2026-11-20 09:09 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-04 Filing 10-Q filed
- 2026-11-04 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-30 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-09-14 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-08-05 Filing 10-Q filed
- 2026-08-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-28 Filing EFFECT filed
- 2026-07-28 Filing 424B3 filed
- 2026-07-17 Filing S-3 filed
- 2026-07-15 Filing 8-K filed: Item 1.01 material agreement; Item 9.01 exhibits
- 2026-07-15 Filing 424B5 filed
- 2026-07-13 Filing EFFECT filed
- 2026-07-13 Filing 424B5 filed
- 2026-07-13 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-07-13 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-06-25 Filing S-3 filed
- 2026-06-16 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-27 Filing 8-K filed: Item 1.01 material agreement; Item 3.02 unregistered equity sale; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-05 Filing 10-Q filed
- 2026-05-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-30 Filing ARS filed
- 2026-04-30 Filing DEFA14A filed
- 2026-04-30 Filing DEF 14A filed
- 2026-04-24 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-04-24 Filing 424B5 filed
8-K item text, as filed (excerpts)
- 2026-11-04 8-K Item 2.02, Results of Operations and Financial Condition
On November 4, 2026, Q32 Bio Inc. announced its financial results for the quarter ended September 30, 2026 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the… the 8-K · retrieved 2026-11-20 09:09 UTC - 2026-08-05 8-K Item 2.02, Results of Operations and Financial Condition
On August 5, 2026, Q32 Bio Inc. announced its financial results for the quarter ended June 30, 2026 and provided a corporate update. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the… the 8-K · retrieved 2026-11-20 09:09 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
EPA RCRA hazardous waste (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | ORBIMED ADVISORS LLC | $52,590,554 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:09 UTC | Report an error |
| 2 | Boxer Capital Management, LLC | $40,122,209 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:09 UTC | Report an error |
| 3 | Atlas Venture Life Science Advisors, LLC | $34,615,930 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:09 UTC | Report an error |
| 4 | BVF INC/IL | $29,939,000 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:09 UTC | Report an error |
| 5 | RA CAPITAL MANAGEMENT, L.P. | $29,715,502 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:09 UTC | Report an error |
| 6 | Point72 Asset Management, L.P. | $14,949,065 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:09 UTC | Report an error |
| 7 | Opaleye Management Inc. | $11,860,940 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:09 UTC | Report an error |
| 8 | Logos Global Management LP | $10,192,000 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:09 UTC | Report an error |
| 9 | SummitTX Capital, L.P. | $9,348,281 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:09 UTC | Report an error |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | $6,609,550 | 2026-06-30 | SEC 13F filing | 2026-11-20 09:09 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
1 state and city record carry this company's exact name, from 1 source. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchQ32 Bio Inc. · exact legal name · sx:ctgov:hfbeb8fb12c54c517 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1661998.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001661998. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.